Drugs / Vusolimogene Oderparepvec
Vusolimogene Oderparepvec
Trials 9 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 01 trial | ||||||
| Phase 0 | NCT06216938 | Mar 2024 → Mar 2028 expected | melanoma | Yana Najjar | Recruiting | No outcome recorded |
| Phase 1/23 trials | ||||||
| Phase 1/2 | NCT06067061 | Apr 2024 → May 2025 | triple-negative breast carcinoma | Institut Curie | Terminated | No outcome recorded |
| Phase 1/2 | NCT05858229 | Jun 2023 → Dec 2025 overdue | skin squamous cell carcinoma | Sherrif Ibrahim | Active not recruiting | No outcome recorded |
| Phase 1/2 | NCT04349436 | May 2020 → Jul 2029 expected | basal cell carcinoma, cutaneous neuroendocrine carcinoma, skin squamous cell carcinoma | Replimune, Inc. | Active not recruiting | No outcome recorded |
| Phase 23 trials | ||||||
| Phase 2 | NCT06898970 | Jan 2026 → Oct 2029 expected | angiosarcoma | Varun Monga, MBBS | Active not recruiting | No outcome recorded |
| Phase 2 | NCT04050436 | Oct 2019 → Sep 2025 overdue | skin squamous cell carcinoma | Replimune, Inc. | Active not recruiting | No outcome recorded |
| Phase 2 | NCT03767348 | Sep 2017 → Jun 2028 expected | cutaneous melanoma, non-small cell lung carcinoma, skin carcinoma | Replimune, Inc. | Active not recruiting | No outcome recorded |
| Phase 31 trial | ||||||
| Phase 3 | NCT06264180 | Jul 2024 → Sep 2030 expected | melanoma | Replimune, Inc. | Recruiting | No outcome recorded |
| Phase not stated1 trial | ||||||
| — | NCT06590480 | — | melanoma | Replimune, Inc. | No longer available | No outcome recorded |
Evidence & citations 6 cited values
Every value below carries the sentence it was read from. 11 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | vusolimogene oderparepvec | “RP1 (vusolimogene oderparepvec) is a herpes simplex virus type 1-based oncolytic immunotherapy” PMID 40627813 ↗ Jul 2025 |
| Known as | Hsv-1 oncolytic viral strain rp1 | ChEMBL registry synonym — accepted as the source's own label CHEMBL4650271 ↗ |
| Known as | Immulytic | “Atezolizumab plus RP1 (Immulytic™) oncolytic immunotherapy” NCT06067061 ↗ |
| Known as | Oncolytic virus rp1 | ChEMBL registry synonym — accepted as the source's own label CHEMBL4650271 ↗ |
| Known as | RP1 | “Vusolimogene oderparepvec (RP1)” NCT06216938 ↗ |
| Route | Other | “RP1 was administered intratumorally” PMID 40627813 ↗ Jul 2025 |